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ABSTRACT
The K1 gene product of Kaposi’s sarcoma-associated herpesvirus (KSHV) is encoded by the first open reading frame (ORF) of
the viral genome. To investigate the role of the K1 gene during the KSHV life cycle, we constructed a set of recombinant viruses
that contained either wild-type (WT) K1, a deleted K1 ORF (KSHVK1), stop codons within the K1 ORF (KSHV-K15STOP), or a
revertant K1 virus (KSHV-K1REV). We report that the recombinant viruses KSHVK1 and KSHV-K15STOP displayed signifi-
cantly reduced lytic replication compared to WT KSHV and KSHV-K1REV upon reactivation from latency. Additionally, cells
infected with the recombinant viruses KSHVK1 and KSHV-K15STOP also yielded smaller amounts of infectious progeny upon
reactivation than did WT KSHV- and KSHV-K1REV-infected cells. Upon reactivation from latency, WT KSHV- and KSHV-
K1REV-infected cells displayed activated Akt kinase, as evidenced by its phosphorylation, while cells infected with viruses deleted
for K1 showed reduced phosphorylation and activation of Akt kinase. Overall, our results suggest that K1 plays an important
role during the KSHV life cycle.
IMPORTANCE
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of three human malignancies, and KSHV K1 is a signal-
ing protein that has been shown to be involved in cellular transformation and to activate the phosphatidylinositol 3-kinase
(PI3K)/Akt/mTOR pathway. In order to investigate the role of the K1 protein in the life cycle of KSHV, we constructed recombi-
nant viruses that were deficient for K1. We found that K1 deletion viruses displayed reduced lytic replication compared to the
WT virus and also yielded smaller numbers of infectious progeny. We report that K1 plays an important role in the life cycle of
KSHV.
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV), alsoknown as human herpesvirus 8, is the causative agent of KS, a
vascular neoplasm of endothelial cell origin (1). KSHV infection is
linked to two B cell lymphoproliferative disorders: primary effu-
sion lymphoma (PEL) and the plasmablastic variant of multicen-
tric Castleman’s disease (MCD) (2–4). KSHV predominantly dis-
plays a latent state in infected cells and in KSHV-associated
tumors, but a small percentage of KSHV-infected cells undergo
reactivation, which is thought to be important for KS tumorigen-
esis (5). KSHV reactivation can occur through multiple events (6,
7), and the KSHV replication and transcription activator (RTA)
protein is the only viral protein that is both necessary and suffi-
cient to reactivate KSHV. The expression of RTA leads to the
activation of downstream lytic genes and ultimately the produc-
tion of progeny virions (8–12).
K1 is a transmembrane glycoprotein encoded by the first open
reading frame (ORF) in the KSHV genome (13). Although K1 is
highly upregulated during the lytic cycle, it has also been shown to
be expressed at lower levels during latency (14). K1 is expressed in
KS lesions and primary effusion lymphoma cell lines (13–17). The
K1 protein contains an immunoreceptor tyrosine-based activa-
tion motif (ITAM) in its cytoplasmic tail, which is involved in
activating signal transduction pathways (4, 17–20). K1 transforms
mouse fibroblasts (21) and immortalizes primary human endo-
thelial cells (22). The transforming activity of K1 is thought to be
conferred through phosphatidylinositol 3-kinase (PI3K)/Akt/
mTOR signaling. The PI3K/Akt/mTOR pathway is activated by
K1 in B and endothelial cells (18, 22), and this provides a survival
advantage to K1-expressing cells (4, 18, 22, 23). K1-expressing
cells also secrete increased amounts of vascular endothelial growth
factor (VEGF), which is an angiogenic factor that promotes vas-
cularization (24). The K1 ITAM is required for signal transduc-
tion in B and endothelial cells (18, 21, 22, 25, 26).
The role of K1-mediated activation of signaling pathways dur-
ing KSHV reactivation from latency has been studied in the con-
text of exogenous expression of K1 (26, 27). However, thus far, a
K1 mutant virus has not been made and tested for its ability to
affect KSHV lytic replication in the context of the whole virus.
In this study, we employed bacterial artificial chromosome
(BAC) technology to construct a set of recombinant KSHVs: wild-
type (WT) K1 (WT KSHV K1), wild-type FLAG-tagged K1
(KSHV-K1FLAG), a K1 deletion virus removing the entire K1 ORF
(KSHVK1), and a K1 mutant virus (KSHV-K15STOP) in which
stop codons were inserted into the K1 ORF to prevent the expres-
sion of the protein. A K1 revertant virus (KSHV-K1REV), in which
a FLAG-tagged K1 coding sequence was restored, was also con-
structed. These different viruses were used to assess the effect of K1
on the KSHV life cycle. We found that deletion of the K1 gene or
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prevention of K1 expression in KSHVK1 or KSHV-K15STOP,
respectively, resulted in decreased production of infectious virus
following reactivation of the virus from latency. Moreover, these
mutant viruses exhibited less phosphorylation of Akt in infected
cells following reactivation. Akt phosphorylation and virus pro-
duction were restored in K1 revertant virus-infected cells com-
pared to K1 mutant virus-infected cells. Our results suggest that
K1 plays an important role in lytic reactivation and replication as
well as the activation of the Akt pathway in infected cells.
MATERIALS AND METHODS
Cell culture and recombinant virus construction. BAC16 and iSLK-RTA
cells were kindly provided by Jae U. Jung (28). Vero and HEK293T cells
harboring WT KSHV, KSHV-K1FLAG, KSHV-K15STOP, KSHV-K1REV,
and KSHVK1 as well as iSLK-RTA and iSLK cells harboring these viruses
were grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomy-
cin. iSLK-RTA cells were cultured in the presence of 1 g/ml puromycin
and 250 g/ml G418. HEK293T cells harboring WT KSHV, KSHV-
K1FLAG, KSHV-K15STOP, KSHV-K1REV, and KSHVK1 were con-
structed and maintained in the presence of 100 g/ml hygromycin. iSLK
cells harboring WT KSHV, and the recombinant viruses KSHV-K1FLAG,
KSHV-K15STOP, KSHV-K1REV, and KSHVK1 were established and
maintained in the presence of 1 g/ml puromycin, 250 g/ml G418, and
1,200 g/ml hygromycin B.
Construction of KSHV-K1FLAG, KSHV-K15STOP, KSHV-K1REV,
and KSHVK1. BAC16 was kindly provided by Jae U. Jung (28).
pcDNA3-WT K1FLAG and pcDNA3-K15STOP were used as the templates
for WT K1 and mutant K1 genes for the construction of recombinant
viruses. pcDNA3 WT K1FLAG, which has a flag epitope tag at the N termi-
nus of WT K1 from the BCBL1 genome and was constructed as previously
described (24). pcDNA3-K15STOP was constructed by the insertion of
the K15STOP fragment into the BamHI and EcoRI sites of pcDNA3 WT
K1FLAG. The pcDNA3-K15STOP construct contains 3 stop codons fol-
lowing the start codon of WT K1FLAG and also has 2 TGA stop codons
instead of ATG codons at positions 481 and 763 to prevent the expression
of WT K1FLAG. The following primers were used: forward 1 (5=-GCAGG
ATCCATGTAAATAGGTGAGCCCTGCCCGTGACCGCCCTG), re-
verse 1 (5=-CGATGGAATTCTCAGTACCAATCCACTGGTTGC), for-
ward 2 (5=-GCAGGATCCATGTAAATAGGTGAGCCCTGCCCGTGAC
CGCCCTG), reverse 2 (5=-GTATAACACCCCTCAGTTTGGTTTCACAG
CGTAAAATTATAGTATTTAG), forward 3 (5=-CACTCGTAGCTCTGAT
AGGAACCTGATGTGGTATCTTAGGAACTATTATC), and reverse 3
(5=-GATAATAGTTCCTAAGATACCACATCAGGTTCCTATCAGAGC
TACGAGTG).
DH10B harboring BAC16 was a gift from Jae U. Jung (28). KSHV-
K1FLAG, KSHV-K15STOP, KSHV-K1REV, and KSHVK1 recombinant
viruses were made by using BAC16. The original K1 gene is located at
positions 105 to 959 in the KSHV BAC16 genome (28) (GenBank acces-
sion number GQ994935). The recombinant viruses KSHV-K1FLAG,
KSHV-K15STOP, KSHV-K1REV, and KSHVK1 were constructed with
the Red/ET recombination system, purchased from Gene Bridges Inc.,
according to the manufacturer’s instruction. This system utilizes a dual-
antibiotic cassette for the positive selection of kanamycin resistance and
negative selection of streptomycin sensitivity rendered by the bacterial
ribosomal protein S12 (rpsL) gene. In brief, a Red/ET expression plas-
mid was transformed into DH10B cells harboring BAC16 with electropo-
ration. Next, an RpsL-neomycin cassette flanked by homologous nucleo-
tides upstream of the original K1 gene and other homologous nucleotides
downstream of K1 was generated by PCR with forward primer
5=-GTGTAAACCTGTCTTTCAGACCTTGTTGGACATCCCGTAC
AATCAAGGGCCTGGTGATGATGGCGGGATCG and reverse primer
5=-CACATTACAATTATGTTACAGAGAATATTTAGATTATC
TTACCTGAATGTCAGAAGAACTCGTCAAGAAGGCG, and the cas-
sette was then electroporated into DH10B-Red/ET cells harboring
BAC16. To replace the K1 gene with the linear RpsL-Neo cassette flanked
by homologous arms, we used L-arabinose in the growth medium to in-
duce the expression of the Red/ET plasmid and allow for recombination.
The transformed bacteria were plated onto LB agar plates and selected
with chloramphenicol and kanamycin. Positive colonies growing under
chloramphenicol and kanamycin selection were isolated and analyzed by
PCR and pulsed-field gel electrophoresis (PFGE). Next, colonies harbor-
ing BAC16 containing the RpsL-Neo cassette in place of the K1 gene were
subjected to a second recombination step. DNA fragments with homolo-
gous arms, including K1FLAG or K15STOP, were amplified by PCR with
forward primer 5=-GTGTAAACCTGTCTTTCAGACCTTGT
TGGACATCCCGTACAATCAAGATGGCCCTGCCCGTGACCGC-
CCTGC and reverse primer CACATTACAATTATGTTACAGAGAAT
ATTTAGATTATCTTACCTGAATGTCAGAAGAACTCGTCAAGAAG
GCG for K1FLAG or forward primer GTGTAAACCTGTCTTTCAGAC
CTTGTTGGACATCCCGTACAATCAAGATGTAAATAGGTGAGCC
CTGC and reverse primer ACACATTACAATTATGTTACAGAGAATAT
TTAGATTATCTTACCTGAATGTCAGTACCAATCCACTGGTTGC
for K15STOP and were transformed into DH10B cells harboring BAC16
with the RpsL-Neo cassette in the K1 location. The bacteria were plated
onto plates containing streptomycin and chloramphenicol, and colonies
were analyzed by using PCR and PFGE to check for correct clones con-
taining full-length K1FLAG or K15STOP, etc., in the original K1 location
and in place of the RpsL-Neo cassette. To make KSHV-K1REV, we re-
peated the above-described procedure to replace the K1 mutant gene first
with the RpsL-Neo cassette and then replaced the RpsL-Neo cassette with
WT K1FLAG. All BAC plasmid DNAs were isolated by the alkaline lysis
method for analysis of restriction digestion or with the NucleoBond BAC
100 kit (Clontech) for sequencing.
Establishment of stably infected HEK293T cells and their deriva-
tives. WT or recombinant virus BAC16 DNA was transfected into
HEK293T cells with Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Briefly, 5 g of DNA was transfected into
HEK293T cells in one well of a 6-well plate. A total of 50 g/ml of hygro-
mycin B was added to the medium for selection at 48 h posttransfection.
The concentration of hygromycin B was increased up to 100g/ml at 96 h
posttransfection. Stable infected HEK293T cells were maintained with
100 g/ml hygromycin B.
Establishment of stably infected iSLK cells and their derivatives.
iSLK cells were cocultured with recombinant virus-infected HEK293T
cells. Briefly, a 2:1 ratio of stable recombinant virus-infected HEK293T
cells was plated with iSLK-RTA cells so that the total number of cells was
2.5  105 cells per well of a 6-well plate. Three milliliters of 2% FBS–
DMEM with final concentrations of 25 ng/ml of tetradecanoyl phorbol
acetate (TPA) and 0.5 mM sodium butyrate was added to the cells at 24 h
postseeding to induce reactivation. Four days later, cells were selected
with 250g/ml G418, 1g/ml puromycin, and 1.2 mg/ml hygromycin B.
Next, recombinant virus-infected stable iSLK cells, which were 100%
green fluorescent protein (GFP) positive, were reactivated with 3 g/ml
doxycycline and 1 mM sodium butyrate for 3 days. The supernatant was
collected, cleared by centrifugation at 950  g for 10 min, and filtered
through a 0.45-m filter. A new batch of uninfected iSLK-RTA cells was
infected with this filtered viral supernatant in the presence of 8 g/ml of
Polybrene and centrifuged for 2 h at 2,500 rpm at 30°C. The cells were then
placed into an incubator with 5% CO2 at 37°C. At 48 h postinfection, 1
g/ml puromycin, 250 g/ml G418, and 1.2 mg/ml hygromycin were
added to the medium to select for stable iSLK-WT KSHV, iSLK-KSHV-
K1FLAG, iSLK-KSHV-K15STOP, KSHV-K1REV, and KSHVK1 cell lines.
These cell lines were maintained in the presence of 1 g/ml puromycin,
250 g/ml G418, and 1.2 mg/ml hygromycin.
Recombinant KSHV DNA purification and analysis. Viral DNA was
isolated from DH10B-BAC cells with the alkaline lysis procedure and
from iSLK cells with the DNeasy kit (Qiagen). Purified BAC DNA from
alkaline lysis was digested with KpnI for analysis by PFGE. Briefly, 3 ml of
BAC16-containing chloramphenicol-resistant bacteria was subjected to
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alkaline lysis. Purified BAC16 DNA was digested with KpnI and separated
on 1% pulsed-field-certified agarose by using PFGE (Chef-Mapper; Bio-
Rad) under the following conditions: 6 V/cm for 15 h at 14°C and initial
and final switch times of 0.1 and 11.15 s, respectively. Recombinant KSHV
DNA purified with the NucleoBond BAC 100 kit was used for sequencing
with the 454 GS Junior sequencer. Finished genomic data were submitted
to GenBank.
Preparation of viruses. A total of 5 105 iSLK-WT and recombinant
virus-infected cells were plated into one well of a 6-well plate overnight,
after which cells were reactivated with 3 g/ml doxycycline in DMEM
with 2% FBS for 72 h. The supernatant was collected and centrifuged at
950  g for 10 min. The supernatant was used for infection studies.
Genomic DNA of recombinant KSHVs was isolated from the supernatant
or infected cells with the DNeasy blood and tissue kit (Qiagen) for the
detection of KSHV genomic copies by quantitative PCR (qPCR).
Infectivity assay. A total of 1.9  104 Vero cells or primary human
umbilical vein endothelial cells (HUVECs) per well in a 96-well plate were
seeded in triplicate for each sample. The next day, 100 l of fresh super-
natant containing WT KSHV or recombinant viruses was added to naive
Vero cells with 8g/ml Polybrene. The plate was centrifuged at 2,500 rpm
at 30°C for 2 h for Vero cells and for 1 h for primary HUVECs. Twenty-
four hours later, the supernatant was removed and washed with DMEM
for Vero cells or EBM-2 (endothelial cell basal medium 2) for primary
HUVECs, and 100 l fresh medium was added. GFP-positive cells were
counted at 72 h postinfection. For flow cytometry analysis, a similar pro-
tocol was performed. A total of 1  105 Vero cells were plated into each
well of a 24-well plate, and 500 l of fresh supernatant containing WT
KSHV or recombinant viruses was added to naive Vero cells. Cells were
collected following trypsinization at 72 h postinfection, washed with Dul-
becco’s phosphate-buffered saline (DPBS) containing 5% bovine serum
albumin (BSA), and analyzed by flow cytometry.
Genomic DNA for qPCR was isolated with the DNeasy blood and
tissue kit (Qiagen) 72 h after infection of Vero cells with WT or recombi-
nant virus.
Analysis of Akt activation. Cells harboring WT KSHV, KSHV-
K1FLAG, KSHV-K15STOP, KSHV-K1REV, and KSHVK1 were serum
starved for 48 h with DMEM. The cells were then treated with 1.5 g/ml
doxycycline for 24, 48, and 72 h. Cells were washed with ice-cold phos-
phate-buffered saline (PBS) containing 1 mmol/liter Na3VO4 and a pro-
tease inhibitor cocktail (Roche) and then lysed in Triton–NP-40 lysis buf-
fer. Western blot analyses were performed with the indicated antibodies,
which were purchased from Cell Signaling Technology.
Real-time PCR for viral load determination. For real-time PCR for
viral load determinations, cells were treated with 1 g/ml doxycycline for
72 h to reactivate the virus. The supernatant was harvested and divided
into two aliquots. For DNase-resistant KSHV genome samples, one ali-
quot of the supernatant was treated with 1 U of DNase at 37°C for 10 min.
Ten micrograms of salmon sperm DNA was added to 200 l of the clari-
fied supernatant prior to purification of viral genomic DNA with the
DNeasy kit (Qiagen) according to the manufacturer’s protocol. Cell pel-
lets were also harvested, and DNA was purified. SYBR green real-time
PCR was performed in a 384-well format by using an ABI Prism 7900
sequence detection system (Applied Biosystems Inc., Foster City, CA). To
build a standard curve for the cycle threshold (CT) versus the genome
copy number, plasmid pcDNA3-ORF57 was serially diluted to known
concentrations in the range of 4 102 to 4  107 plasmid molecules/l.
Each PCR mixture contained 4 l of viral DNA isolated from the super-
natant or 1 l of viral DNA isolated from the cell pellet, 7.5 l of SYBR
green 2 PCR mix (Applied Biosystems), and 0.05 l each 100 M
ORF57 primer, and the final volume of 15 l was standardized by the
addition of DNase- and RNase-free water (Sigma). Primers for amplifica-
tion of the ORF57 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) genes were ORF57 forward primer 5=-CAGGATGACGACGT
CAGAC, ORF57 reverse primer 5=-GAGCGGTGATATCCCTGTCC-3=,
GAPDH forward primer 5=-GAAGGTGAAGGTCGGAGT, and GAPDH
reverse primer 5=-GAAGATGGTGATGGGATTTC.
Western blot analysis. A total of 5  105 cells per well were seeded
into a 6-well plate. The next day, cells were treated with 1.5 g/ml doxy-
cycline for 24, 48, and 72 h. The cells were scraped and lysed, and the lysate
was mixed with 2 Laemmli buffer. Forty micrograms of each protein
sample was subjected to SDS-PAGE and transferred onto a nitrocellulose
membrane. Western blot analyses were performed with rabbit viral inter-
leukin-6 (vIL-6) polyclonal antibody (1:1,000 dilution; ABI), rabbit anti-
pAkt-S473 antibody (1:1,000; Cell Signaling), horseradish peroxidase-
conjugated FLAG M2 monoclonal antibody (1:500 dilution; Sigma),
mouse anti-K8 monoclonal antibody (1:1,000; Santa Cruz Biotechnol-
ogy), mouse anti-KSHV ORF45 monoclonal antibody (1:1,000; Thermo
Scientific), and antitubulin horseradish peroxidase (HRP)-conjugated
polyclonal antibody.
Accession numbers. The sequence data for the recombinant viruses
have been submitted to GenBank under accession numbers KX189626,
KX189627, KX189628, and KX189629.
RESULTS
Construction of KSHV-K1FLAG, KSHV-K15STOP, KSHV-
K1REV, and KSHVK1 BAC clones derived from WT KSHV
BAC (BAC16). BAC16 is a KSHV BAC clone derived from the
KSHV JSC1 strain as previously described (28). BAC16 has
green fluorescent protein under the control of the EF-1 pro-
moter to indicate KSHV infection. To assess the role of K1 in
the KSHV genome, we either deleted the K1 ORF by replacing
it with an RpsL-Neo cassette or replaced the WT K1 ORF with
a FLAG-tagged K1 gene or a K1 gene with five stop codons.
Using BAC mutagenesis, we made KSHVK1, KSHV-K1FLAG,
KSHV-K15STOP, and a revertant virus, KSHV-K1REV. KSHV-
K15STOP has a mutant K15STOP gene that contains 5 stop
codons, 3 of which are inserted following the first start codon of
K1 and the other 2 of which replace two downstream ATG
codons at positions 481 and 763 in the K1 gene. Hence, KSHV-
K15STOP is not able to express any full-length K1 protein or
any one of the possible shorter ORFs within K1. A schematic
diagram of WT K1 and the modified or mutant K1 genes in the
recombinant viruses is shown in Fig. 1A. The recombinant vi-
rus KSHV-K1REV has a WT K1FLAG ORF replacing the mutant
K1 ORF.
Analysis of the genomic integrity of candidate clones. Ten to
twenty candidates for each clone were picked for PCR and PFGE
analysis. After WT KSHV K1FLAG, mutant KSHV K15STOP, or the
RpsL-Neo cassette was identified to be present in the candidate
clone genomes by PCR (data not shown), the PCR products of
K1, K1FLAG, K15STOP, and the RpsL-Neo cassette were ampli-
fied from WT KSHV, KSHV-K1FLAG, KSHV-K15STOP, and
KSHVK1 candidate clones, respectively. These products were
sequenced to confirm their sequences and matched to the previ-
ously reported sequences (GenBank accession numbers
GQ994935 and U86667). The integrity, sequence, and position of
these genes were confirmed by next-generation whole-genome
sequencing. All viruses (WT KSHV, KSHV-K1FLAG, KSHV-
K15STOP, KSHV-K1REV, and KSHVK1) matched sequences in
the database.
For PFGE analysis, digestion of BAC16 and each candidate
virus with KpnI revealed various sizes of KSHV DNA fragments,
which matched the predicted digestion pattern and fragment sizes
based on the previously reported BAC16 sequence (Fig. 1B). A
high-molecular-weight fragment of 32.7 kb appears in WT KSHV,
Role of KSHV K1 in the Viral Life Cycle
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and a 33.2-kb fragment appears in the KSHVK1 sample contain-
ing the RpsL-Neo cassette. In the KSHV-K1FLAG, KSHV-K1REV,
and KSHV-K15STOP constructs, a 29.7-kb fragment appears be-
cause a new KpnI site at position 196 of KSHV-K1FLAG, KSHV-
K1REV, and KSHV-K15STOP BAC16 was created due to the fact
that WT K1FLAG or K15STOP was substituted in place of the orig-
inal K1 gene of BAC16. The original K1 gene and RpsL-Neo cas-
sette have no KpnI site. PFGE analysis demonstrated the integrity
of the candidate viral genomes.
K1 is required for Akt phosphorylation. We next investigated
the biology of the K1 mutant viruses in the doxycycline-inducible
KSHV-infected iSLK line, which was described by Myoung and
Ganem (29). Previously, we reported that the PI3K/Akt/mTOR
pathway is activated in cells expressing K1 (18, 22). To examine
this pathway in cells infected with the recombinant viruses de-
scribed above, we investigated phosphorylation of Akt by Western
blotting. We found that Akt was phosphorylated at serine 473
(S473) at 72 h postreactivation (with 1.5g/ml of doxycycline) in
cells latently infected with WT KSHV and KSHV-K1FLAG but not
in cells infected with the recombinant viruses KSHVK1 and
KSHV-K15STOP (Fig. 2A). In KSHV-K1REV-infected cells, we
found that the level of phosphorylated Akt at S473 was restored
after reactivation from latency (Fig. 2A). As a control for efficient
reactivation, we also performed Western blotting for KSHV
vIL-6 and found that cells infected with WT KSHV and KSHV-
K1FLAG expressed much higher levels of vIL-6 than did cells
infected with the recombinant viruses KSHVK1 and KSHV-
K15STOP (Fig. 2A).
To elucidate our observations further, we compared Akt phos-
phorylation and viral lytic gene expression 24, 48, and 72 h after
reactivation with 1.5 g/ml of doxycycline. We found that the
level of phosphorylated Akt at S473 increased at several time
points following reactivation for WT KSHV-, KSHV-K1FLAG-,
and KSHV-K1REV-infected cells but not for KSHVK1- and
KSHV-K15STOP-infected cells. Following reactivation, the lytic
K8 and ORF45 proteins were detectable in WT KSHV-, KSHV-
K1FLAG-, and KSHV-K1REV-infected cells but were barely detect-
able in KSHVK1- and KSHV-K15STOP-infected cells (Fig. 2B).
To further confirm that the K1 gene augments viral lytic repli-
cation, we performed an immunofluorescence assay with an anti-
body against the viral lytic protein ORF59. The number of red
fluorescence-labeled ORF59 cells was distinctly higher for WT
KSHV-, KSHV-K1FLAG-, and KSHV-K1REV-infected cells than for
KSHVK1- and KSHV-K15STOP-infected cells at 72 h postreac-
tivation (Fig. 2C and D).
To determine whether K1 could be detected at the protein level
in uninduced iSLK cells, we performed immunoprecipitation
from infected cells using anti-FLAG to pull down K1FLAG. Immu-
noprecipitates using FLAG antibody from iSLK cells latently in-
fected with KSHV-K1FLAG, KSHV-K1, and KSHV-K1REV were
run on SDS-PAGE gels and subjected to Western blot analysis
with an anti-FLAG antibody. As shown in Fig. 3, we were able to
detect K1 expression in cells following immunoprecipitation. Our
results are concordant with those reported by Chandriani and
Ganem, who reported that K1 can be detected in latently infected
cells (14).
K1 deletion from KSHV results in reduced lytic replication of
KSHV. To test the role of K1 during viral replication, we reacti-
vated iSLK cells with doxycycline. We observed greater total GFP
fluorescence in cells harboring WT KSHV, KSHV-K1FLAG, and
KSHV-K1REV than in KSHVK1- and KSHV-K15STOP-infected
iSLK cells following reactivation (Fig. 4A and B). The GFP fluo-
rescence in WT KSHV-, KSHV-K1FLAG-, and KSHV-K1REV-in-
fected cells ranged from 4- to 8-fold higher than that in
KSHVK1- and KSHV-K15STOP-infected cells (Fig. 4C).
To quantify viral genomes, we extracted DNA from cell-free
supernatants and lysates of recombinant virus-infected cells fol-
lowing reactivation. We performed quantitative real-time PCR to
determine the CT values and genome copy numbers. In the super-
natants, the genome copy numbers of released viruses from in-
duced cells harboring WT KSHV, KSHV-K1FLAG, and KSHV-
FIG 1 Construction of wild-type or mutant K1 recombinant viruses. (A)
Schematic diagram of WT K1 and mutant K1 genes. The gray bar represents a
FLAG epitope tag, and each star represents a stop codon. (B) PFGE analysis of
KpnI-digested DNA of BAC16 and its derivatives. DNAs of WT KSHV
(BAC16) and its derivatives KSHV-K1FLAG, KSHV-K15STOP, KSHV-K1REV,
and KSHVK1 were digested with KpnI and analyzed by PFGE. The 29.7-kb
fragment is the result of replacing the original WT K1 gene with FLAG-tagged
K1 and the presence of an additional KpnI site in the FLAG-tagged K1 gene
compared to the WT K1 gene. The 33.2-kb fragment in the KSHVK1 virus is
due to the replacement of the K1 ORF with the Kan-Neo (RpsL-Neo) cassette.
Zhang et al.
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K1REV were markedly higher than those from cells harboring
KSHV-K15STOP and KSHVK1 (Fig. 5A). Following reactiva-
tion, WT KSHV, KSHV-K1FLAG, and KSHV-K1REV displayed a
5-fold increase in virion production, as measured by viral ge-
nomes, compared to KSHVK1 and KSHV-K15STOP (1  10
5
genome copies versus 2  104 genome copies) (Fig. 5A). Similar
results were observed for intracellular genome copy numbers in
reactivated cell lysates from cells that harbored WT KSHV,
KSHV-K1FLAG, and KSHV-K1REV compared to cells harboring
KSHV-K15STOP and KSHVK1 (Fig. 5B).
In order to measure capsid-protected viral DNA, WT KSHV-,
KSHV-K1FLAG-, KSHV-K1REV-, KSHVK1-, and KSHV-K15STOP-
infected iSLK cells were reactivated as described above. The super-
natants were harvested and subjected to DNase treatment for 1 h,
after which viral genomic DNA was harvested and quantitated.
Once again, we observed that WT KSHV, KSHV-K1FLAG, and
KSHV-K1REV displayed a 5- to 6-fold increase in virion produc-
tion (as measured by viral genomes) compared to KSHVK1 and
KSHV-K15STOP (Fig. 5C).
K1 deletion from KSHV results in decreased production of
infectious virions. To test the infectivity of viruses produced from
reactivated cells, cell-free supernatants from reactivated cells were
used to infect naive Vero cells in triplicate, as described in Mate-
rials and Methods. GFP-positive cells were observed at 72 h
postinfection (Fig. 6A). We observed more GFP-positive, i.e., in-
fected, cells from supernatants of WT KSHV-, KSHV-K1FLAG-,
and KSHV-K1REV-infected cells than from KSHVK1- and
KSHV-K15STOP-infected cells. The number of GFP-positive cells
FIG 2 K1 is required for Akt phosphorylation and lytic gene expression in reactivated cells. (A and B) A total of 5  105 WT KSHV-, KSHV-K1FLAG-,
KSHV-K15STOP-, KSHV-K1REV-, and KSHVK1-infected iSLK cells were seeded overnight and then treated with 1.5 g/ml of doxycycline for 72 h (A) or for
24, 48, and 72 h (B). Cells were harvested, lysed, and subjected to Western blot analysis with an anti-FLAG antibody to detect K1, an anti-pAkt (S473) antibody
to detect phosphorylated Akt, an anti-vIL-6 antibody to detect vIL-6, an anti-K8 antibody to detect K8, and an anti-ORF45 antibody to detect ORF45. (C) A
total of 2 105 cells were seeded overnight and then treated with 3 g/ml of doxycycline for 72 h. Cells were fixed with 3.7% formaldehyde and subjected to an
immunofluorescence assay with primary anti-ORF59 antibody (1:500; Advanced Biotechnologies) and secondary anti-mouse IgG antibody conjugated to
tetramethyl rhodamine isocyanate (1:500). (D) Graph depicting the number of quantitated ORF59-positive cells per field following reactivation.
FIG 3 Small amounts of K1 protein are expressed in uninduced KSHV-in-
fected iSLK cells. iSLK cells latently infected with KSHV-K1FLAG, KSHV-
K1REV, and KSHVK1 were harvested and subjected to immunoprecipitation
(IP) with an anti-FLAG antibody to immunoprecipitate FLAG-tagged K1 and
then subjected to Western blot (WB) analysis with an anti-FLAG-HRP-con-
jugated antibody.
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in six random fields for each recombinant virus-infected sample
was quantified (Fig. 6B). The numbers of infectious virions from
reactivated cells harboring WT KSHV, KSHV-K1FLAG, and
KSHV-K1REV were found to be dramatically higher than those
from cells harboring KSHV-K15STOP and KSHVK1.
To further assess the production of infectious virus and quan-
tify the number of KSHV-infected Vero cells, infected cells were
also subjected to flow cytometry analysis. Figure 6C shows that the
percentages of GFP-positive Vero cells were 12.5%, 10.8%, 3.0%,
3.2%, and 14.1% for WT KSHV, KSHV-K1FLAG, KSHVK1,
KSHV-K15STOP, and KSHV-K1REV, respectively, indicating that,
similar to our microscopic quantitation described above, the per-
centages of KSHV-infected Vero cells were higher with WT
KSHV, KSHV-K1FLAG, and KSHV-K1REV viruses than with
KSHVK1 and KSHV-K15STOP viruses.
To confirm the optical readout, we harvested infected Vero
cells as described in the legend of Fig. 6A, extracted DNA, and
performed real-time qPCR for viral genomes. We found that the
numbers of viral genomes were higher in reactivated cells harbor-
ing WT KSHV, KSHV-K1FLAG, and KSHV-K1REV than in cells
harboring KSHV-K15STOP and KSHVK1 viruses (Fig. 6D).
To further assess the infectivity of these viruses on a more rel-
evant cell line, we harvested supernatants from reactivated KSHV-
infected iSLK cells and infected primary HUVECs. Similar to the
case with Vero cells, the numbers of GFP-positive primary
HUVECs were significantly higher following infection with WT
KSHV, KSHV-K1FLAG, and KSHV-K1REV than with KSHVK1
and KSHV-K15STOP (Fig. 7A and B).
DISCUSSION
The KSHV K1 gene has a dramatic impact on cell signaling in
single-gene assays and, in the context of herpesvirus saimiri
(HVS), can replace the HVS-transforming protein, STP (30). In
order to investigate the role of the KSHV K1 ORF in the life cycle
of KSHV, we constructed a set of K1 deletion or K1 mutant re-
combinant viruses, including KSHV-K1FLAG, KSHV-K15STOP,
FIG 4 KSHV K1 is required for efficient reactivation from latency. (A and B) A total of 5 105 stable iSLK cells latently infected with WT KSHV, KSHV-K1FLAG,
KSHV-K15STOP, KSHV-K1REV, and KSHVK1 were plated and examined by fluorescence microscopy in the absence of any induction (A) or after being treated
with 1 g/ml of doxycycline in DMEM supplemented with 2% FBS for 72 h (B). Images were taken at a4 magnification. hpi, hours postinfection. (C) Graph
depicting the number of GFP-positive cells per field that were quantitated following reactivation.
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FIG5 KSHV K1 is required for efficient viral replication. Stable iSLK cells latently infected with WT KSHV, KSHV-K1FLAG, KSHV-K15STOP, KSHV-K1REV, and
KSHVK1 were treated with 1 g/ml of doxycycline for 72 h. Following reactivation, the supernatants (A and C) and cells (B) were harvested for qPCR to
determine viral genome copy numbers. (A) KSHV genome copy numbers in the supernatants of reactivated WT KSHV-, KSHV-K1FLAG-, KSHV-K15STOP-,
KSHV-K1REV-, and KSHVK1-infected iSLK cells. (B) Quantification of intracellular viral genome copy numbers present in cells of reactivated WT KSHV-,
KSHV-K1FLAG-, KSHV-K15STOP-, KSHV-K1REV-, and KSHVK1-infected iSLK cells. For normalization across samples, intracellular viral genome copy
numbers were normalized to the intracellular CT value of GAPDH. (C) KSHV genome copy numbers from DNase-treated and untreated supernatants of
reactivated WT KSHV-, KSHV-K1FLAG-, KSHV-K15STOP-, KSHV-K1REV-, and KSHVK1-infected iSLK cells.
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FIG 6 KSHV K1 is required for efficient infectious virion production. Supernatants from reactivated WT KSHV-, KSHV-K1FLAG-, KSHV-K15STOP-, KSHV-
K1REV-, and KSHVK1-infected iSLK cells were used to infect naive Vero cells for 72 h. (A) GFP-positive cells were imaged by fluorescence microscopy at 72 h
postinfection (hpi) at a 20 magnification. (B) Graph depicting numbers of GFP-positive cells per field. (C) Supernatants from reactivated WT KSHV-,
KSHV-K1FLAG-, KSHV-K15STOP-, KSHV-K1REV-, and KSHVK1-infected iSLK cells were used to infect naive Vero cells for 72 h, and infected cells were
analyzed by flow cytometry for the percentage of GFP-positive cells to quantitate infectivity. (D) Infected Vero cells from panel A were harvested, and the
intracellular viral genome copies present in infected cells were quantified by real-time PCR. For normalization across samples, intracellular viral genome copy
numbers were normalized to the intracellular CT value of GAPDH. FITC, fluorescein isothiocyanate; SSC-A, side-scattered light area.
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KSHV-K1REV, and KSHVK1. JSC-1-derived recombinant
KSHV BAC16 (28) was used as the parental BAC for the construc-
tion of K1 deletion or mutant recombinant viruses. The integrity
and sequences of all the WT KSHV, KSHV-K1FLAG, KSHV-
K15STOP, KSHV-K1REV, and KSHVK1 genomes in this study
were identified and verified by multiple independent methods,
including whole-genome sequencing. We also epitope tagged the
K1 gene with the FLAG epitope in the context of the virus to use it
as a tool for investigating K1 function during the KSHV life cycle.
Previously, our laboratory and other groups studied K1 signal
transduction events (4, 14, 17-20, 22). We reported that K1 acti-
vates the PI3K/Akt/mTOR pathway and provides a survival ad-
vantage to K1-expressing cells (18, 22). Here, we extended these
studies and found that cells that were infected with K1 deletion or
mutant viruses (KSHV-K15STOP and KSHV-K1) displayed
lower phospho-Akt levels than cells infected with viruses contain-
ing WT K1. We detected low levels of K1 expression in cells in-
fected with KSHV-K1FLAG using coimmunoprecipitation. This
finding correlates with data from previous reports suggesting that
K1 can be expressed under latency conditions (14, 22). However,
we cannot rule out the possibility that the K1 that we are detecting
is due to a low level of lytic replication in infected iSLK cells.
All iSLK cells harboring WT KSHV, KSHV-K1FLAG, KSHV-
K15STOP, KSHV-K1REV, or KSHVK1 were able to produce
infectious virus in response to doxycycline induction; however,
viruses lacking the K1 gene, including KSHV-K15STOP and
KSHV-K1, were significantly attenuated for viral reactivation in
response to RTA induction. Accumulating evidence suggests that
lytic replication may play a prominent role in KS (5, 31–34), and
our data suggest that K1 is involved in enhancing lytic reactivation
and/or replication. Several groups have investigated the link be-
tween K1 signal transduction and KSHV reactivation by the over-
expression of K1 or deletion mutants (26, 27). Lagunoff et al.
reported that the expression of lytic cycle genes was diminished up
to 80% in the presence of a K1 dominant negative mutant, which
inhibited wild-type K1 signal transduction in BCBL-1 cells that
were induced into reactivation by the ectopic expression of the
KSHV ORF50 transactivator (26). Our results demonstrate that
deletion of K1 using the deletion virus KSHVK1 as well as the
recombinant virus KSHV-K15STOP displayed reduced KSHV re-
activation as measured by vIL-6 lytic gene expression, KSHV ge-
nome copy numbers, and the production of infectious viruses. In
contrast, a revertant virus, where mutant K1 was restored back to
WT K1, grew similarly to KSHV-K1FLAG. Collectively, our data
indicate that the lack of K1 protein expression leads to decreased
production of KSHV infectious virions. However, the exact mech-
anism by which this occurs is yet to be determined. In conclusion,
we have shown that KSHV K1 plays an important role in the
KSHV viral life cycle.
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